EUVIMEDEUVIMED entdecken
LeserbriefKommentarOpen Access

Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy

Christian F Guerrero-Juarez, Parul K Goyal, Kyle T Amber iD

British Journal of Dermatology · 2023

DOI: 10.1093/bjd/ljad324 ↗

Kurz gefasst

Leserbrief in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Christian F Guerrero-Juarez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Carle Illinois College of Medicine, University of Illinois, Urbana-Champaign, Urbana. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Melanoma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 4 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institute of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of dupilumab has been suggested in the treatment of immune checkpoint inhibitor (ICI)-induced bullous pemphigoid. In this letter, we express caution with the targeted inhibition of the Th2 pathway given current evidence suggesting the beneficial effect of the Th2 response, particularly eosinophilia, to ICI responses, particularly in melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousMelanomaHumansInterleukin-13Immune Checkpoint InhibitorsImmunotherapy

Substanzen

Interleukin-13Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Carle Illinois College of Medicine, University of Illinois, Urbana-Champaign, Urbana.
  • Department of Dermatology, Rush University Medical Center, Chicago.
  • Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA.

ORCID-Profile: Kyle T Amber

Förderung

  • NIH HHS
  • National Institute of Health

Zitieren

APA

Guerrero-Juarez, C. F., Goyal, P. K., & Amber, K. T. (2023). Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad324

Vancouver

Guerrero-Juarez CF, Goyal PK, Amber KT. Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy. British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad324

BibTeX
@article{GuerreroJuarez2023,
  author = {Guerrero-Juarez, Christian F and Goyal, Parul K and Amber, Kyle T},
  title = {Targeting interleukin (IL)-4/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy},
  journal = {British Journal of Dermatology},
  year = {2023},
  doi = {10.1093/bjd/ljad324}
}
Kostenlos starten →